14.10.2015 • NewsChairmanDede Willamshealthcare

Stefan Oschmann to Head Germany’s Merck

Stefan Oschmann has been named as new chief executive of Germany’s Merck...
Stefan Oschmann has been named as new chief executive of Germany’s Merck KGaA, succeeding current CEO Karl-Ludwig Kley, who will retire following the German chemical and pharmaceutical producer’s annual general meeting on Apr. 29, 2016.

Stefan Oschmann has been named as new chief executive of Germany’s Merck KGaA, succeeding current CEO Karl-Ludwig Kley, who will retire following the German chemical and pharmaceutical producer’s annual general meeting on Apr. 29, 2016. A member of the Merck executive board since 2011, the 58-year-old manager was initially in charge of the pharmaceutical business. At the beginning of 2015, he was named deputy chairman and CEO, responsible for strategy and innovation.

During the nine-year tenure of the now 64-year-old Kley as head of Merck, the company has gone through the biggest transformation in its almost 350-year history, said Johannes Baillou, chairman of the Board of Partners at E. Merck, parent of the Merck group. 

From a company with a diverse portfolio in pharma and chemicals in 2006, Baillou noted that Merck has evolved into a specialized high-tech company in healthcare, life science and performance materials. Following mergers and acquisitions worth about €38 billion as well as organic growth, sales this year are expected to be twice the 2005 level. Two change programs have resulted in a leaner organization capable of driving innovation more efficiently.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.